2021
DOI: 10.3390/pathogens10060674
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence and Genetic Diversity of Group A Rotavirus Genotypes in Moscow (2019–2020)

Abstract: Group A rotavirus (RVA) infection is the leading cause of hospitalization of children under 5 years old, presenting with symptoms of acute gastroenteritis. The aim of our study was to explore the genetic diversity of RVA among patients admitted to Moscow Infectious Disease Clinical Hospital No. 1 with symptoms of acute gastroenteritis. A total of 653 samples were collected from May 2019 through March 2020. Out of them, 135 (20.67%) fecal samples were found to be positive for rotavirus antigen by ELISA. RT-PCR … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 34 publications
0
3
0
Order By: Relevance
“…However, the effectiveness of RVA vaccines has been higher in high-income countries (80%–90%) than in low-to-middle income countries (40%–70%) [ 3 ], and there is still much work to be done in reducing the disease's global impact. Furthermore, a long-term impact of RVA vaccines on genetic diversity of circulating RVAs has been observed in many neighboring countries of China, including Korea, Japan, Thailand, and Russia [ [4] , [5] , [6] , [7] , [8] ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, the effectiveness of RVA vaccines has been higher in high-income countries (80%–90%) than in low-to-middle income countries (40%–70%) [ 3 ], and there is still much work to be done in reducing the disease's global impact. Furthermore, a long-term impact of RVA vaccines on genetic diversity of circulating RVAs has been observed in many neighboring countries of China, including Korea, Japan, Thailand, and Russia [ [4] , [5] , [6] , [7] , [8] ].…”
Section: Introductionmentioning
confidence: 99%
“…In 2001, the Lanzhou Lamb RV vaccine (LLR) became the only domestic RV vaccine licensed in China [ 9 , 10 ] with more than 83 million doses of LLR lot-released as of October 2019 [ 11 ]. At the end of 2018, the MSD RotaTeq vaccine (G1-G4, G9, P [ 5 ]) was also licensed in China. In addition, two novel RVA vaccines, LLR3 (G2-G4) and pentavalent (G1-G4, G8-G9), finished phase III clinical trials in China [ [11] , [12] , [13] ].…”
Section: Introductionmentioning
confidence: 99%
“…Due to the use of RV vaccines, reductions in diarrhea and hospital admissions have been observed in many countries. The criterion for successful vaccination is high coverage of the target population, and the higher the vaccine coverage, the greater the significant reductions in hospitalization rates for RVA [ 7 , 8 , 9 ]. RV vaccines do not fully protect young children against infection, but it does reduce the severity of the infection.…”
Section: Introductionmentioning
confidence: 99%